Friends of Cancer Research has published three white papers that focus on the development of external controls, the assessment of combination immuno-oncology therapies for patients with disease progression, and the generation of data for companion diagnostics.
Last week, Richard Pazdur was named to the position of director of FDA’s Center for Drug Evaluation and Research. Much has been written about how Pazdur, with nearly a three-decade long career at the agency, represents a stabilizing choice for FDA as it faces inner and outer turmoil.
